Three months after Bristol Myers Squibb revealed the success of two phase 3 trials of its oral targeted therapy Sotyktu in ...

Adults and adolescents treated with icotrokinra experienced improvements in their moderate to severe plaque psoriasis, ...

which is set to continue thanks to myeloma blockbuster Revlimid and new psoriasis and psoriatic arthritis drug Otezla. Celgene has been one of the sector's most spectacular success stories of ...

Otezla was acquired by Amgen for $13.4 billion when Celgene was ... corner the market for psoriasis pills. Analysts at Mizuho have suggested that competition from BMS' drug could trim Otezla's ...

In the plaque psoriasis arena, Sotyktu is facing off ... a report from Spherix Global Insights found that Amgen’s oral drug Otezla—which incidentally Amgen acquired from BMS subsidiary Celgene—“has ...

Alumis Inc.'s twice-a-day oral drug totally cleared the skin of telltale red, itchy patches in nearly 39% of 80 ...

Advancements in biologics, personalized medicine, and rising global prevalence drive the psoriasis treatment market's exponential growth.Pune, March 12, 2025 (GLOBE NEWSWIRE) -- Psoriasis Treatment ...

Johnson & Johnson’s once-daily oral peptide has bested Bristol Myers Squibb’s reigning oral psoriasis med Sotyktu in a ...

Late-stage data also showed that Johnson & Johnson’s icotrokinra was superior to Bristol Myers Squibb’s Sotyktu at clearing ...